News & Featured Coverage

Navigating Capital As A Woman: Janet Qi Of PurMinds Neuropharma On Top Strategies for Women Founders, CEOs and Leaders Seeking Institutional Investments: An Interview with Vanessa Ogle

Psychedelic Community Reacts To FDA Committee's Critique Of Lykos' MDMA Studies

PurMinds NeuroPharma Announces Its First Botanical Psilocybin Delivery to Bluestem API Inc.

PurMinds NeuroPharma Announces PUR501 as Lead Candidate Novel Non-Hallucinogenic Neuroplastogen

PurMinds Neuropharma's CEO, Janet Qi, has been featured in Clinical Leader’s latest article, "The Best Advice I Ever Got: On The Job"

PurMinds Chief Scientific Officer to Speak at the 4th Annual Psychedelic Therapeutics and Drug Development Conference

PurMinds NeuroPharma appoints Vanessa Williamson as Chief Business Officer

Rethinking Mental Health: How Emerging Therapies Are Changing the Game

Supplying Complex, Controversial, And Intercontinental Clinical Trials

ALS: how close are we to a cure?

Interviews: Neurological Breakthroughs and Mindful Living: Janet Qi’s PurMinds Revolution

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond

Wonderland 2023: Pureminds NeuroPharma With Janet Qi

PurMinds Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco

Cross Time Report: PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board

Wonderland Conference Miami: Bridging Psychedelics And Overall Wellness

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Recent Coverage: Psychedelics and health at the forefront for upcoming Wonderland Miami

PurMinds NeuroPharma Chief Innovation Officer to Speak at Wonderland Conference